Compare · KZR vs RNA
KZR vs RNA
Side-by-side comparison of Kezar Life Sciences Inc. (KZR) and Atrium Therapeutics Inc. (RNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KZR and RNA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- RNA is the larger of the two at $133.8M, about 2.5x KZR ($53.7M).
- Over the past year, KZR is up 14.8% and RNA is down 83.9% - KZR leads by 98.7 points.
- RNA has hit the wire 12 times in the past 4 weeks while KZR has been quiet.
- RNA has more recent analyst coverage (25 ratings vs 7 for KZR).
- Company
- Kezar Life Sciences Inc.
- Atrium Therapeutics Inc.
- Price
- $7.30-1.02%
- $7.68-1.60%
- Market cap
- $53.7M
- $133.8M
- 1M return
- -0.68%
- -19.49%
- 1Y return
- +14.78%
- -83.94%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 0
- 12
- Recent ratings
- 7
- 25
Kezar Life Sciences Inc.
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.
Atrium Therapeutics Inc.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.
Latest KZR
- SEC Form 15-12G filed by Kezar Life Sciences Inc.
- SEC Form EFFECT filed by Kezar Life Sciences Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Kezar Life Sciences Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Kezar Life Sciences Inc.
- Director Berger Franklin M closing all direct ownership in the company (SEC Form 4) to satisfy tax liability
- SEC Form 4 filed by Director Garner Elizabeth
- SEC Form 4 filed by Director Cooper Graham K
- Director Kauffman Michael closing all direct ownership in the company (SEC Form 4) (withholding obligation)
- SEC Form 4 filed by Director Wallace Courtney
- CEO Kirk Christopher J. closing all direct ownership in the company (SEC Form 4) (tax liability)
Latest RNA
- Amendment: SEC Form 8-K/A filed by Atrium Therapeutics Inc.
- SEC Form 8-K filed by Atrium Therapeutics Inc.
- Atrium Therapeutics Announces $50 Million Private Placement
- Chief Scientific Officer Younis Husam covered exercise/tax liability with 11,216 shares, decreasing direct ownership by 21% to 41,441 units (SEC Form 4) to cover taxes
- Chief Medical Officer Hughes Steven George covered exercise/tax liability with 21,459 shares, decreasing direct ownership by 29% to 51,638 units (SEC Form 4) to satisfy withholding tax
- Director Boyce Sarah covered exercise/tax liability with 126,418 shares, decreasing direct ownership by 48% to 138,668 units (SEC Form 4) (withholding obligation)
- Director Flanagan W. Michael covered exercise/tax liability with 22,812 shares, decreasing direct ownership by 42% to 31,974 units (SEC Form 4) to satisfy withholding tax
- Officer Kenney Stephanie covered exercise/tax liability with 2,375 shares, decreasing direct ownership by 7% to 33,085 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Winslow Brendan R. covered exercise/tax liability with 6,742 shares, decreasing direct ownership by 15% to 36,859 units (SEC Form 4) (for withholding tax)
- Officer Gallagher Kathleen P. covered exercise/tax liability with 11,632 shares, decreasing direct ownership by 9% to 119,729 units (SEC Form 4) (for tax liability)